Dr. Chris Junker joined BAT in 2025 as Group Head of Life Sciences. In his role, Chris is accountable for the strategic direction of the life sciences research programme and delivery of scientific evidence to support BAT’s smokeless product portfolio and, more broadly, tobacco harm reduction.

Prior to his role with BAT, Chris served as Vice President, Scientific & Regulatory Affairs for Reynolds American Inc., a wholly owned subsidiary of BAT. In this prior role, he was responsible for regulatory strategy and engagement, leading a multidisciplinary team of scientists and regulatory experts in the synthesis of premarket regulatory submissions for Reynolds’ electronic nicotine delivery systems (ENDS) and oral tobacco product portfolios.